LATTUADA, Emanuela
 Distribuzione geografica
Continente #
NA - Nord America 1.032
EU - Europa 778
AS - Asia 303
SA - Sud America 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.120
Nazione #
US - Stati Uniti d'America 1.025
GB - Regno Unito 269
CN - Cina 268
SE - Svezia 109
IE - Irlanda 90
FR - Francia 79
IT - Italia 69
DE - Germania 59
FI - Finlandia 58
UA - Ucraina 22
KR - Corea 10
TR - Turchia 8
BE - Belgio 7
CA - Canada 7
VN - Vietnam 7
RU - Federazione Russa 6
IN - India 3
NL - Olanda 3
CL - Cile 2
IL - Israele 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
KW - Kuwait 1
KZ - Kazakistan 1
NO - Norvegia 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 2.120
Città #
Southend 246
Chandler 235
Jacksonville 152
Woodbridge 127
Dublin 90
Ann Arbor 70
Ashburn 49
Beijing 47
Houston 36
Lawrence 33
Princeton 33
Jinan 32
Wilmington 29
Shenyang 27
Helsinki 23
Nanjing 23
New York 20
Hebei 15
Nanchang 11
Ningbo 11
Seoul 10
Verona 10
Tianjin 9
Changsha 8
Haikou 8
Hangzhou 8
Redmond 8
Sindelfingen 8
Brussels 7
Jiaxing 7
Lanzhou 7
Zhengzhou 7
Clearwater 6
Milan 6
Norwalk 6
San Francisco 6
Taizhou 6
Boardman 5
Bologna 5
Dong Ket 5
Pignone 5
Toronto 5
Guangzhou 4
Scandiano 4
Taiyuan 4
Vicenza 4
Bursa 3
Düsseldorf 3
Fairfield 3
Falls Church 3
Fuzhou 3
Giussano 3
Redwood City 3
Riva 3
Seattle 3
Groningen 2
Los Angeles 2
Montréal 2
San Diego 2
Washington 2
Albinea 1
Andover 1
Bratislava 1
Buenos Aires 1
Büdelsdorf 1
Cairo 1
Chicago 1
Dearborn 1
Dongguan 1
Fushan 1
Indianapolis 1
Kharkov 1
Kuwait City 1
Lancaster 1
Landshut 1
Leawood 1
Moscow 1
Nashville 1
Novokuznetsk 1
Nürnberg 1
Oslo 1
Paarl 1
Saint Louis 1
Salford 1
San Jose 1
Secunderabad 1
Shenzhen 1
Torino 1
Venezia 1
Villaricca 1
Totale 1.544
Nome #
Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load 104
Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life 89
Pneumatocoele formation during Pneumocystis carinii pneumonia in a man with HIV-1 infection. 89
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient 83
Acute mediastinitis: a severe complication of transdermal therapy in a patient with ischaemic heart disease. A case report. 79
No improvement of lipodystrophy syndrome in an HIV-infected patient. 77
Histoplasmosis in two human immunodeficiency virus-positive immigrants to Italy: clinical features and management in the highly active antiretroviral therapy era. 77
Raltegravir: is a 400 mg once-daily dose enough? 76
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients 76
Recreational substance use and tolerance of efavirenz in HIV-1 infected patients 74
Is there a role for TNF-alpha in HIV1-associated lipodystrophy? 74
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption. 73
Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients 73
Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report. 70
Monoclonal gammopathy in HIV-Infected patients on stable antiretroviral therapy: disappearance or deep reduction? 68
'High' antiretroviral deintensification strategy and cellular HIV DNA levels 68
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir 63
No influence of nevirapine on vitamin D deficiency in HIV-infected patients 62
Efficacy and safety of TAM-sparing antiretroviral regimens in naive HIV-positive patients 60
Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report 60
mIRTAZAPINE IN AN HIV-INFECTED PATIENT WITH PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 59
Prevalence and clinical significance of Ureaplasma urealyticum and Mycoplasma hominis in the lower genital tract of HIV-1-infected women. 58
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study 58
Efavirenz dose reduction in HIV-infected patients: a long-term follow-up 56
Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor 56
Short-Cycle Therapy (5 days on/2 days off) with a lamivudine-dolutegravir two-drug regimen in a cohort of virologically suppressed HIV-infected patients 56
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials 51
Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings 51
Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients 49
Relationship between vertebral fractures, bone mineral density, and osteometabolic profile in HIV and Hepatitis B and C-infected patients treated with ART 48
Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up 46
Prior Mycobacterium avium complex infection is linked to immunological nonresponsiveness in HIV-infected patients on highly active antiretroviral therapy 45
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients 45
Short-cycle therapy in {HIV}-infected adults: rilpivirine combination 4 days on/3 days off therapy 10
Totale 2.183
Categoria #
all - tutte 7.210
article - articoli 7.210
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.420


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20198 0 0 0 0 0 0 0 0 0 0 4 4
2019/2020283 37 2 4 13 39 48 30 18 8 20 25 39
2020/2021284 43 38 13 32 39 26 7 22 16 13 24 11
2021/2022303 29 107 1 25 2 3 3 19 15 11 16 72
2022/2023620 36 85 50 94 62 154 0 39 77 2 10 11
2023/2024213 16 26 30 21 36 48 2 17 3 14 0 0
Totale 2.183